CC
INZY

Corton Capital’s Inozyme Pharma INZY Stock Holding History

Corton Capital’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,056
Closed -$62.7K – 575
2024
Q2 		$62.7K Buy
+14,056
New +$68.2K 0.03% 464
2022
Q2 		– Sell
-11,350
Closed -$46K – 422
2022
Q1 		$46K Buy
+11,350
New +$66.8K 0.02% 416

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corton Capital's INZY Position: Q3 2024 in Review

Corton Capital sold out of Inozyme Pharma (INZY) in Q3 2024, closing a stake of 14,056 shares — an estimated $62.7K sold.

Corton Capital first reported a position in INZY in Q1 2022 and held it in 2 quarters. The position peaked at $62.7K in Q2 2024. 89 funds tracked by Wall St. Rank hold INZY as of Q3 2024.

  • Corton Capital reported no remaining Inozyme Pharma position as of Q3 2024 after selling out during the quarter.
  • Corton Capital sold 14,056 Inozyme Pharma shares in Q3 2024, an estimated $62.7K.
  • Corton Capital first reported a position in Inozyme Pharma in Q1 2022 and held it in 2 quarters.
  • Corton Capital's Inozyme Pharma position peaked at $62.7K in Q2 2024.
  • 89 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2024.

Based on Corton Capital's 13F filing for Q3 2024, filed 14 Nov 2024.